Integrum AB Class B (INTEG.B) AI Stock Analysis

• Market Cap: €898.18M
• Dividend Yield: N/A
• Average Volume (3M): 185.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -12.50%
• EPS Growth: -783.92%
• Country: SE
• Employees: 36
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Devices
• EPS (TTM): -0.44
• Shares Outstanding: 20,694,328
• 10 Day Avg. Volume: 103,469
• 30 Day Avg. Volume: 185,891
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €44.03
• Price Target Upside: 4.45% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: kr44.00 ▲(4.39% Upside)

The stock score is primarily driven by strong technical analysis, indicating bullish market momentum. However, financial performance challenges and poor valuation metrics weigh heavily on the overall score. The absence of earnings call insights or notable corporate events maintains focus on existing financial and technical data.

Integrum AB Class B Business Overview & Revenue Model

Company Description

Integrum AB Class B (INTEG.B) is a Swedish medical technology company specializing in the development of innovative systems for bone-anchored prosthetics. The company operates within the healthcare and medical device sectors, focusing on improving the quality of life for amputees. Integrum's core product, the OPRA Implant System, is a proprietary solution that offers a unique method of attaching prosthetic limbs directly to the bone, providing improved functionality and comfort compared to traditional socket prosthetics.

How the Company Makes Money

Integrum AB generates revenue primarily through the sale of its OPRA Implant System to healthcare providers and clinics around the world. The company earns money by manufacturing and distributing these advanced prosthetic solutions, which are typically covered by insurance providers or paid for by healthcare institutions. Additionally, Integrum may engage in strategic partnerships with medical device companies or healthcare organizations to expand the adoption of its technology. The company's earnings are also bolstered by ongoing research and development efforts, which may lead to new product offerings or enhancements to existing systems, thus attracting more customers.

Integrum AB Class B Financial Statement Overview

Summary

Integrum AB is facing financial difficulties, with declining revenues and increasing losses. Despite a strong equity position, profitability and cash flow generation are major concerns. Operational challenges are evident, but the stable balance sheet provides some support.

Income Statement

Integrum AB's income statement shows a declining trend in revenue with a significant drop from 2024 to 2025. The gross profit margin remains relatively high, indicating efficient cost management in production. However, the company has faced increasing operating losses, as seen in the negative EBIT and EBITDA margins, signaling challenges in covering operational expenses. Net profit margins have also deteriorated, reflecting overall financial struggles in maintaining profitability.

Balance Sheet

The balance sheet demonstrates a strong equity position with a high equity ratio, indicating financial stability and a lower reliance on debt. The debt-to-equity ratio is low, which is favorable and shows prudent financial management. Return on equity, however, is negative, reflecting the company's inability to generate profit from its equity base. Overall, the balance sheet is stable with potential for leveraging equity for growth.

Cash Flow

Cash flow analysis reveals consistent challenges in generating positive operating cash flow, contributing to negative free cash flow. The operating cash flow to net income ratio indicates difficulties in converting income to cash. Financing activities have been a source of cash, but reliance on external financing could pose risks if not managed carefully. There is a negative trend in free cash flow growth, pointing to potential liquidity concerns.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	91.10M	104.12M	74.27M	55.72M	43.09M
Gross Profit	75.38M	91.26M	60.84M	46.56M	34.89M
EBITDA	-35.50M	8.76M	-20.24M	2.60M	-1.59M
Net Income	-30.85M	4.03M	-16.18M	21.27M	-2.14M
Balance Sheet
Total Assets	203.25M	164.86M	165.17M	180.44M	37.21M
Cash, Cash Equivalents and Short-Term Investments	39.60M	16.90M	41.92M	75.34M	7.66M
Total Debt	4.84M	6.42M	7.92M	580.89K	485.92K
Total Liabilities	25.38M	22.07M	21.64M	20.70M	12.91M
Stockholders Equity	177.88M	142.79M	143.53M	159.74M	24.29M
Cash Flow
Free Cash Flow	-50.59M	-24.37M	-36.50M	-49.55M	-7.47M
Operating Cash Flow	-37.70M	-12.74M	-25.10M	-20.28M	-5.76M
Investing Cash Flow	-12.89M	-11.63M	-11.40M	-29.27M	-1.71M
Financing Cash Flow	73.29M	-648.54K	3.08M	117.23M	2.06M

Integrum AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 42.15 is above the 20-day moving average (MA) of 39.67, above the 50-day MA of 28.04, and above the 200-day MA of 20.41, indicating a bullish trend. The MACD of 4.54 indicates Positive momentum. The RSI at 88.75 is Negative, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INTEG.B	62 Neutral	€898.18M	―	-19.17%	―	-12.50%	-783.92%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.26%	22.80%	-2.27%
BRAIN	50 Neutral	kr408.97M	―	-33.54%	―	44.16%	35.06%
DOXA	49 Neutral	kr633.77M	―	-51.41%	―	3.57%	-925.35%
ACARIX	46 Neutral	kr395.71M	―	-88.97%	―	9.27%	52.03%
MNTC	45 Neutral	kr392.35M	―	-45.57%	―	-6.82%	-449.86%
QLINEA	41 Neutral	kr313.97M	―	-190.21%	―	16.98%	36.29%